Table 1.
Baseline demographic and clinical characteristics
| Variable | n (%) or median (IQR)* |
|---|---|
| Median (IQR) age (years) | 11 (9.0 – 14.0) |
| Age (years) | |
| 6 – 9 | 7 (28%) |
| 10 – 14 | 13 (52%) |
| 15 – 17 | 5 (20%) |
| Sex | |
| Male | 15 (60%) |
| Female | 10 (40%) |
| Body weight (kg) | 30.0 (24.5 – 40.5) |
| Height (cm) | 132.0 (128.2 – 152.7) |
| Body mass index (kg/m2) | 16.7 (15.6 – 17.6) |
| Weight band | |
| 20 to < 25 kg | 6 (24%) |
| 25 to < 30 kg | 4 (16%) |
| 30 to < 40 kg | 9 (36%) |
| ≥ 40 kg | 6 (24%) |
| Previous ART | |
| Tenofovir disoproxil/ lamivudine/ efavirenz | 6 (24%) |
| Zidovudine/lamivudine/efavirenz | 17 (68%) |
| Tenofovir disoproxil/ lamivudine/lopinavir/ritonavir | 2 (8%) |
| Study regimen | |
| Tenofovir disoproxil/lamivudine/dolutegravir | 16 (64%) |
| Zidovudine/lamivudine/dolutegravir | 7 (28%) |
| Abacavir/lamivudine/dolutegravir | 2 (8%) |
| Entry HIV RNA | |
| < 20 copies/mL or target not detected | 21 (84%) |
| 20 - < 200 copies/mL | 2 (8%) |
| 200 - < 1000 copies/mL | 0 (0%) |
| > 1000 copies/mL | 2 (8%) |
| Time since HIV diagnosis (years) | 6.3 (1.8 – 10.8) |
| Time on prior ART (years) | 6.3 (1.9 – 10.8) |
| White blood cell count (x 109/L) | 4.4 (4.1 – 5.4) |
| Absolute neutrophil count (x 109/L) | 1.1 (0.9 – 1.9) |
| Hemoglobin (g/dL) | 11.6 (10.4 – 12.1) |
| Platelets (x 109/L) | 312 (264 – 365) |
| Blood urea nitrogen (mmol/L) | 2.5 (2.0 – 3.20) |
| Serum creatinine (μmol/L) | 39.0 (31.4 – 46.6) |
| Aspartate transaminase (IU/L) | 27.5 (22.3 – 40.8) |
| Alanine transaminase (IU/L) | 17.8 (12.3 – 29.3) |
| Alkaline phosphatase (IU/L) | 249 (151 – 279) |
| Total bilirubin (μmol/L) | 4.58 (3.7 – 6.4) |
| Direct bilirubin (μmol/L) | 1.0 (1.0 – 1.0) |
| Albumin (g/L) | 39.5 (35.3 – 41.9) |
*
number (percent) or median (interquartile range)